EGFR and non-small cell lung carcinoma: Significantly higher c-Myc levels in different EGFRm NSCLC cell lines with acquired resistance to osimertinib and in patients with relapsed EGFR-TKIs treatment compared to their corresponding parental cell lines (Zhu et al., 2021a).